New Course Offering: Developability Assessment – The Logical Approach to Discovery Lead Selection

If you work in drug discovery, you know the disheartening statistics: Only 0.4% of compounds in development ever reach the market, and companies can spend $1.4 billion on average to get a single pharmaceutical on the market. With so much risk, it’s natural that biotechnology companies, pharmaceutical researchers and contract research organizations (CROs) are seeking ways to bend the odds in their favor.

That’s why we’re pleased to offer a new course: Developability Assessment – The Logical Approach to Discovery Lead Selection, taught by Dr. Duane Lakings. An expert in drug metabolism, Dr. Lakings became a champion of developability assessment in the late 1980s when he was working in drug discovery and development at the Upjohn Company. A compound for hypertension was in development, which needed to have high bioavailability to ensure its success. However, the compound proved to have a lower bioavailability than required. This demerit with what might have otherwise been a feasible compound led Dr. Lakings to create developability assessment guidelines that have since become a gold standard for drug discovery.

Developability Assessment allows you to engineer the drug discovery pathway to ensure your compound not only makes it to the research and development stage, but also allows you to clearly document its desired attributes and potential demerits early in the planning stages.

With no FDA oversight at this early stage of drug discovery, careful planning is sometimes overlooked in favor of pushing compounds through the process as quickly as possible. This is a costly, avoidable error that proper developability assessment can correct.

To attend Dr. Lakings course and learn more about improving your odds of developing successful compounds, register on the course page or call 1-610-648-7550. Early bird pricing is available.